Companies Dominating the Adiponectin Testing Landscape
- STRATEC SE
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Laboratory Corporation of America Holdings
- Bio-Rad Laboratories, Inc.
- Boster Biological Technology
- Thermo Fisher Scientific Inc.
- Eagle Biosciences, Inc.
- Merck KGaA
- ERBA Diagnostics, Inc.
- Zeus Scientific Inc.
- Trinity Biotech plc
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of adiponectin testing is estimated at USD 2.7 billion.
The adiponectin testing market size was valued at USD 2.36 billion in 2024 and is set to exceed USD 6.9 billion by 2037, expanding at over 8.6% CAGR during the forecast period i.e., between 2025-2037. Increasing adoption of adipose-derived products and the higher prevalence of cardio-metabolic diseases globally will boost the market growth.
North America industry is estimated to hold largest revenue share by 2037, attributed to rising cases of cardiometabolic diseases and a growing population with obesity.
The major players in the market are STRATEC SE, Laboratory Corporation of America Holdings, Bio-Rad Laboratories, Inc., Boster Biological Technology, Thermo Fisher Scientific Inc., Eagle Biosciences, Inc., Merck KGaA, ERBA Diagnostics, Inc., Zeus Scientific Inc., Trinity Biotech plc
